| Name | Title | Contact Details |
|---|
Angion Biomedica Corp. is a late-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel small molecule therapeutics to address acute organ injuries and fibrotic diseases. Angion`s lead product candidate, ANG-3777, is a small molecule designed to mimic the biological activity of hepatocyte growth factor (HGF) to activate the HGF/c-Met pathway, which has a central role in tissue repair and organ recovery. Enrollment is ongoing in a placebo-controlled Phase 3 registration trial examining the efficacy of ANG-3777 in reducing the severity of transplant-associated acute kidney injury, also known as delayed graft function, in patients at risk for kidney dysfunction. ANG-3777 is also in a Phase 2 clinical trial for the treatment of acute kidney injury associated with cardiac surgery involving cardiopulmonary bypass. Angion is also developing ANG-3070, an orally-bioavailable small molecule, as a potential treatment for a variety of chronic fibrotic diseases sharing similar underlying disease-driving pathways identified and targeted using a precision-medicine approach.
Creo is an ingredient company that produces rare and novel cannabinoids using the age-old natural process of fermentation, coupled with cutting-edge technological innovation. Founded in 2016 and based in California, Creo`s mission is to enable the creation of cannabinoid products that help people everywhere while doing less harm to the planet. Creo`s technology partner and major shareholder is industry-leading biotech firm Genomatica.
SHYFT has been an integral part of the life sciences ecosystem for over 10 years and as the market undergoes a dramatic transformation to deliver more personalized and value-based medicine, the role of SHYFT has never been more important. We built the SHYFT Platform to help life science companies integrate clinical and commercial data and translate it into patient-centric intelligence and analytics for use across functional groups, shortening development cycles and commercialization activities while improving the probability of success. With a long history of success and deep client partnerships, we understand the market transformation and the actionable intelligence required for successful launch, growth and maintenance of new therapies. At SHYFT, we collaborate with our clients to ensure their success not only today, but in the future by providing flexible, agile solutions based on deep industry expertise. With an impressive customer retention rate, we`re committed to our client`s success and serve as a true partner in the transformation.
Bioinformatics.org is a Framingham, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
ACGT DNA Technologies is a Toronto, ON-based company in the Healthcare, Pharmaceuticals, & Biotech sector.